Publications by authors named "M P Deek"
Unresectable stage III non-small-cell lung cancer (NSCLC) remains a clinical challenge, due to the need for optimal local and systemic control. The management of unresectable Stage III NSCLC has evolved with advancements in radiation therapy (RT), systemic therapies, and immunotherapy. For patients with locally advanced NSCLC who are not surgical candidates, concurrent chemoradiotherapy (CRT) has modest survival outcomes, due to both local progression and distant metastasis.
View Article and Find Full Text PDFBackground: Tumor suppressors are well known drivers of cancer invasion and metastasis in metastatic castration sensitive prostate cancer (mCSPC). However, oncogenes are also known to be altered in this state, however the frequency and prognosis of these alterations are unclear. Thus, we aimed to study the spectrum of oncogene mutations in mCSPC and study the significance of these alteration on outcomes.
View Article and Find Full Text PDFArticle Synopsis
- This study explored the use of diffusion-weighted MRI to evaluate prostate cancer patients with Gleason score 7 tumors before radiotherapy, focusing on the correlation between MRI results, cancer characteristics, and treatment outcomes.
- It was found that tumors classified as GS 3+4 had higher ADC values compared to GS 4+3 tumors, indicating a difference in disease aggression, with lower ADC values linked to poorer survival rates.
- The research concluded that ADC values could serve as an effective biomarker to distinguish between different types of GS 7 tumors, with lower values correlating with a higher risk of disease progression and worse long-term outcomes.
Article Synopsis
- - There is a need for better tools to help manage oligometastatic castration-sensitive prostate cancer (omCSPC), as highlighted in a retrospective study examining the effectiveness of the ArteraAI Prostate Test.
- - This study involved 222 men and measured outcomes like overall survival (OS) and time until the cancer becomes castration-resistant, finding a high MMAI score linked to worse OS and shorter time to resistance.
- - Additionally, the study indicated that patients with high MMAI scores who received metastasis-directed therapy (MDT) had improved metastasis-free survival compared to those with low scores, pointing to the potential of the MMAI biomarker for guiding treatment decisions.
Purpose: To assess the early metabolic response of the primary tumor using Gallium-68 (Ga)-labeled-prostate-specific membrane antigen positron emission tomography (Ga-PSMA-PET/CT), as well as the relationship between PSMA change in the primary tumor and PSA response after definitive radiotherapy (RT), either alone or in combination with androgen deprivation therapy (ADT) in intermediate risk prostate cancer (IR-PCa) patients.
Methods: The clinical data of 71 IR-PCa patients treated with RT alone (36 patients, 50.7%) or RT and ADT (35 patients, 49.